HAL (France)open access
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Inflammatory Bowel Disease, Biologic Agent, 0, TNF Inhibitor, Monoclonal Antibody
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 643353
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.